期刊文献+

289例药疹临床分析 被引量:1

Clinical analysis of 289 cases with drug eruption
下载PDF
导出
摘要 目的:探讨临床应用药物与药疹发生的关系以及药疹的防治。方法:对我院皮肤科自2000年1月~2006年12月间因药疹到门诊就诊或住院的患者的临床资料进行分析。结果:289例患者中有196例可明确为1种致敏药物,占67.8%(196/289)。由青霉素类引起的药疹共有71例,占36.2%(71/196),其中阿莫西林45例,安西林21例,苄星青霉素G5例。磺胺类引起的药疹共有36例,占18.4%(36/196)。解热镇痛药引起的药疹共有56例,占28.6%(56/196),其中扑热息痛24例,吲哚美辛26例。青霉素类及解热镇痛药引起的药疹中重症药疹分别占8.5%(6/71)及8.9%(5/56)。巴比妥类引起的药疹共13例,占6.6%(13/196),其中重症药疹占38.5%(5/13)。治疗所需的糖皮质激素控制剂量多为80~120mg/d,病程较长。结论:青霉素类、解热镇痛类及磺胺类药物是引起药疹最常见的药物。引起重症药疹的药物主要为青霉素类、解热镇痛药以及巴比妥类。 Objective To discuss the connection between clinical drugs and drug eruption as well as the prevention of drug eruption. Method The clinical data were analyzed for drug eruption of out - patients or in - patients in the department of dermatology in our hospital from January 2000 to December 2006. Results For 196 out of 289 patients were confirmed to be caused by a sensitizing drug (67.8% in ratio). Seventy -one cases were caused by BenzylpeniciUin (36.2%), including 43 by Amoxicillin, 21 by Ancillin and 5 by Benzathine Benzylpenieillin. Thirty - six eases were caused by Sulfanilamide ( 18.4% ). Fifty - six cases were caused by non - steroidal antiinflammatory drugs (28.6%), including 24 by Paracetamol Granules and 26 by indometacin. Among those caused by Benzylpenicillin and non - steroidal antiinflammatory, 8.5% (6/71) and 8.9% (5/56) were severe. In addition, 13 cases were caused by Barbital (6.6%) , including 38.5% (5/13) severe cases. Dosage control of Glucocorticoids for treatment was 80 -120 mg/d and the duration of treatment was a bit longer than normal. Conclusion Benzylpenicillin, non - steroidal antiinflammatory and Sulfonamides are the most common drugs that might cause drug eruption. Drugs that might cause severe drug eruption include enzylpenicillin, non - steroidal antiinflammatory and Barbital.
出处 《吉林医学》 CAS 2008年第11期906-908,共3页 Jilin Medical Journal
关键词 药疹 青霉素类 解热镇痛类 巴比妥类 Drug eruption BenzylpeniciUin non - steroidal antilnflammatory Barbital
  • 相关文献

参考文献4

二级参考文献17

  • 1Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol,2001, 44: 1010-1024.
  • 2Pyne D, Ehrenstein M, Morris V.The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.Rheumatology (Oxford). 2002, 41: 367-374.
  • 3Gelfand EW. Use of IGIV in the treatment of immune-mediated dermatologic disorders.J Investig Dermatol Symp Proc, 2004, 9:92-96.
  • 4Akashi K, Nagasawa K, Mayumi T, et al.Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol, 1990, 17:375-379.
  • 5Maier WP, Gordon DS, Howard RF, et al.Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum, 1990,33: 1233-1239.
  • 6Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol, 1994, 21: 1092-1097.
  • 7Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies:experience based on controlled clinical trials. Neurol Sci, 2003, 24: S256-259.
  • 8Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol, 1996, 35:1150-1153.
  • 9Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM, 2000, 93: 433-439.
  • 10Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol, 2003, 139: 1051-1059.

共引文献105

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部